

VIP Very Important Paper

Stereoselective Synthesis of 2-Oxyenamides**

Sara-Cathrin Krieg^{+, [a]}, Jennifer Grimmer^{+, [a]}, Annika Maria Pick,^[a] Harald Kelm,^[a] Martin Breugst,^[b, c] and Georg Manolikakes^{*, [a]}

Dedicated to Herbert Mayr on the occasion of his 75th birthday

An improved route for the highly stereoselective synthesis of (Z)-2-oxyenamides is reported. The desired products can be accessed in only three steps from aminoacetaldehyde dimethyl acetal as common, readily available building block in a highly

modular fashion. The improved procedure has been applied to the synthesis of various acylated and sulfonylated oxyenamides. Mechanistic and theoretical studies provide a conclusive rationale for the observed stereoselectivities.

Introduction

Enamides and the corresponding encarbamates constitute a class of versatile building blocks for organic synthesis.^[1] Due to the electron-withdrawing group on the nitrogen, they display an increased chemical stability compared to the parent enamines together with a diminished but still notable nucleophilic character (Figure 1). This delicate balance between reactivity and stability renders enamides excellent substrates for the synthesis of highly functionalized amines and nitrogen-containing heterocycles. Apart from their application in asymmetric hydrogenation reactions for the synthesis of chiral amines,^[1a] enamides have been successfully utilized in the highly stereoselective construction of various nitrogen-containing scaffolds.^[1,2]

Furthermore, the enamide moiety is frequently found in natural products.^[3] In stark contrast, synthesis and application of 2-oxyenamides, enamide derivatives containing an additional oxygen functionality at the β -carbon, has been sparsely studied so far.^[4] The 2-(3H)-oxazolone heterocycle, a cyclic 2-oxy-enamide mostly studied in cycloaddition reactions, is the only notable exception.^[5] Interestingly, the 2-oxyenamide motif is




Figure 1. Enamines, enamides, encarbamates, 2-oxyenamides and 2-(3H)-oxazolone.

also present in some natural products, e.g. the pacidamycins^[6] and sansanmycins^[7] from the uridyl peptide family or the miruraenamides, a class of cyclic polyketide-peptide hybrids (Figure 2).^[8]

We have recently described the application of (Z)-2-oxyenamides in the diastereoselective synthesis of 1,3-diamino-2-alcohols.^[9] Our studies showed that 2-oxyenamides display a similar reactivity pattern as their parent carbon-substituted enamides and could serve as new type of building block for the stereoselective construction of the 1,2-aminoalcohol scaffold.




Figure 2. 2-Oxyenamide containing natural products.

[a] S.-C. Krieg,⁺ J. Grimmer,⁺ A. M. Pick, Dr. H. Kelm, Prof. Dr. G. Manolikakes
Department of Chemistry, Technical University Kaiserslautern,
Erwin-Schrödinger-Str. Geb 54, 67663 Kaiserslautern, Germany
E-mail: manolikakes@chemie.uni-kl.de
<https://www.chemie.uni-kl.de/manolikakes>

[b] Prof. Dr. M. Breugst
Department of Chemistry, University of Cologne
GreinstraÙe 4, 50939 Köln, Germany
E-mail: mbreugst@uni-koeln.de

[c] Prof. Dr. M. Breugst
Institut für Chemie, TU Chemnitz
Straße der Nationen 62, 09111 Chemnitz, Germany
E-mail: martin.breugst@chemie.tu-chemnitz.de

[⁺] These authors contributed equally to this work.

[**] A previous version of this manuscript has been deposited on a preprint server (<https://doi.org/10.26434/chemrxiv-2022-59zzw>).


Supporting information for this article is available on the WWW under <https://doi.org/10.1002/ejoc.202200772>

© 2022 The Authors. European Journal of Organic Chemistry published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.


Key to their successful application was the development of a stereoselective preparation of the required (*Z*)-2-oxyenamides. In our preliminary communication, we reported the synthesis of five selected (*Z*)-2-oxyenamides and (*Z*)-2-oxyencarbamates bearing an acyl functionality on the oxygen atom. Herein, we disclose an improved synthetic route towards 2-oxyenamides, 2-oxyencarbamates and 2-oxyenimides with an expanded substrate scope. Furthermore, we provide mechanistic studies which help to rationalize the highly stereoselective formation of the (*Z*)-configured oxyenamides.

Results and Discussion

At the beginning of our studies, we selected acyl-protected 2-oxyenamides of type 1/2 as most promising substrates for our purposes (Scheme 1). At first, the electron-withdrawing acyl group on the oxygen substituent should render the embedded enol ester moiety less nucleophilic than the enamide functionality.^[10] In turn, a chemoselective reaction with electrophiles should occur on the β -carbon (highlighted in blue). Furthermore, we envisioned, that 2-acyloxyenamides should be



Scheme 1. Retrosynthetic rationale towards 2-acyloxyenamides.



Scheme 2. 1st generation route via IBX oxidation. [a] The reaction was carried out with Ac_2O (1.3 equiv), NEt_3 (1.7 equiv) and DMAP (0.2 equiv). Bz = benzoyl; Piv = pivaloyl; Ac = acetyl; Boc = *tert*-butoxycarbonyl; Cbz = benzyloxycarbonyl.

readily accessible from the corresponding protected amino aldehyde 3. Finally, incorporation of an ester functionality should facilitate further manipulations, such as deprotection to the free alcohol.

In our initial studies, protected 2-aminoacetaldehyde derivatives were prepared in two steps from 2-aminoethanol 6 (Scheme 2). Selective *N*-acylation afforded the *N*-protected aminoalcohols 4a–c in 64–68% yield. Oxidation with IBX furnished the three aldehydes 3a–c in 92–95% yield. In general, aldehydes of type 3 are not stable. We observed a more or less rapid decomposition upon storage at ambient temperature, in particular in solution. Therefore, the *N*-protected aminoacetaldehydes (3) were always synthesized on demand and directly utilized in the subsequent step. Treatment of 3 with the appropriate acid chloride and NEt_3 in CH_2Cl_2 furnished the desired 2-oxyenamides (1a–c) and 2-oxyencarbamates (2a and 2b) in 56–73% yield. The acetyl-protected 2-oxyenamides 2b was synthesized from aldehyde 2a using acetic anhydride as acylating agent in the presence of 20 mol% DMAP.^[11] Interestingly, exclusive formation of the (*Z*)-isomer was observed for all products.^[12]

Effects of deviations from the standard reaction conditions for the final oxyenamide formation are summarized in Table 1. Replacement of DIPEA with NEt_3 afforded the desired product in comparable yield and excellent *Z*-selectivity (entry 2). The use of other organic bases led to either reduced yields (DBU and DBN; entry 3 and 4) or a complete shutdown of the reaction (pyridine, DMAP or DABCO, entries 5–7). Inorganic bases such as K_2CO_3 and NaOMe furnished only trace amounts of the expected product. (entries 8–9). Similar yields of the oxyenamide 1a were obtained in THF, CHCl_3 or MeCN (entries 10–12). Substitution of CH_2Cl_2 with DMF or toluene led to reduced yields of 37% and 61% (entries 13–14). Again, exclusive

Table 1. Investigation of the reaction conditions.


Entry	Deviations from standard conditions	Yield [%] ^[a]	<i>E</i> : <i>Z</i> ratio ^[b]
1	standard conditions	81, 73 ^[c]	< 2:98
2	DIPEA instead of NEt_3	71	< 2:98
3	DBU instead of NEt_3	69	< 2:98
4	DBN instead of NEt_3	38	< 2:98
5	pyridine instead of NEt_3	nr	-
6	DMAP instead of NEt_3	nr	-
7	DABCO instead of NEt_3	nr	-
8	K_2CO_3 instead of NEt_3 , solvent MeCN	traces	< 2:98
9	NaOMe instead of NEt_3 , solvent MeCN	traces	< 2:98
10	THF instead of CH_2Cl_2	75	< 2:98
11	CHCl_3 instead of CH_2Cl_2	77	< 2:98
12	MeCN instead of CH_2Cl_2	80	< 2:98
13	DMF instead of CH_2Cl_2	37	< 2:98
14	toluene instead of CH_2Cl_2	61	< 2:98

[a] Yields were determined by ^1H NMR spectroscopy using CH_2Br_2 as internal standard. [b] The *E*:*Z* ratio was determined by ^1H NMR of the crude product. [c] Isolated yield.


formation of the *Z*-isomer was observed in all cases. It has to be mentioned that all 2-oxyenamides are moderately sensitive towards acid and some simple precautions have to be taken in order to avoid decomposition (see experimental section/supporting information for further details).

In the further course of our work, we realized that, although proceeding with high chemoselectivity and efficiency, IBX could be problematic for a systematic exploration of the substrate scope and scale-up studies. On the one hand the use of IBX could lead to oxidation of other oxidation-sensitive functional groups. On the other hand, the commercial availability of IBX is rather limited.^[13] In addition, we encountered problems with regards to reproducibility during the scale-up of the oxidation. Therefore, we decided to explore a redox-neutral route from aminoacetaldehyde dimethyl acetal **7**, a readily available bulk chemical (Scheme 3).

Reaction of **7** with benzoyl chloride in the presence of NEt₃ afforded the protected aminoacetaldehyde derivative **5a** in



Scheme 3. 2nd generation route and scale-up.




Scheme 4. Synthesis of *N*-protected protected aminoacetaldehyde dimethyl acetal derivatives **5b–p**. [a] Reaction conditions: K₂CO₃ (3.0 equiv), Et₂O/water (1:1), 0°C to rt, 16 h. Fmoc = fluorenylmethoxycarbonyl.


99% yield.^[14] Cleavage of the acetal with aqueous HCl in THF^[14] proceeded rapidly, furnishing the desired free aldehyde in 99% yield after a simple aqueous work-up. Direct treatment of the obtained crude aldehyde **3a** with our standard reaction conditions led to the 2-oxyenamide **1a** in identical yield and stereoselectivities. This modified procedure greatly facilitated scale-up of our oxyenamide synthesis. Using the 2nd generation approach, we routinely synthesized 3.5 g batches of 2-benzoyloxyenamide **1a** in 65–70% overall yield from cheap aminoacetaldehyde dimethyl acetal **7**.

In the further course of our studies, we prepared various *N*-protected aminoacetaldehyde dimethyl acetal derivatives **5b–p** in high to excellent yields (Scheme 4). Aromatic and aliphatic residues (R¹) were incorporated with similar efficiencies. The introduction of carbamoyl-based protecting groups, proceeded in the same manner, affording the Boc-, Cbz- or Fmoc-protected products **5b–d** in 89–96% yield.

Next, the obtained acetals were hydrolyzed with aq. HCl in THF (Scheme 5). Efficient cleavage was observed in almost all cases and the corresponding aldehydes **3c–n** were isolated in 48–98% yield and sufficient purity after aqueous workup. Only in the case of the acid-labile Boc-protected acetal **5b** and two acetals with an aliphatic residue (**5o–p**) the formation of the desired product could not be observed. The formed crude aldehydes were directly subjected to the next step, the base-mediated enol ester formation (Scheme 6). Reactions with different *N*-protected protected aminoacetaldehydes containing an aromatic or heteroaromatic amide functionality proceeded smoothly, affording the expected 2-oxyenamides **1c–n** 52–87% yield, always as analytically pure *Z*-isomer. Whereas, treatment of the cyclohexylamide derivative **2n** with benzoyl chloride led to the formation of the 2-oxyenamide **1n** in 85% yield, a slightly reduced yield was observed for *meta*-toluoyl derivative **1l**. On the other hand, reactions with the carbamates **2c–d** delivered the desired Cbz- and Fmoc-protected oxyencarbamates **1c** and **1d** in 59% and 67% yield. Treatment of the




Scheme 5. Synthesis of *N*-protected protected aminoacetaldehydes **3c–n** via acetal hydrolysis.



Scheme 6. Synthesis of 2-oxyenamides **1/2** and enol sulfonates **8a–c** – substrate scope. [a] The reaction was carried out with Ac₂O (1.3 equiv), NEt₃ (1.7 equiv) and DMAP (0.2 equiv).

aldehyde **3a** with different benzoic acid chlorides furnished the expected 2-oxyenamides **2a–p** in high yields and excellent stereoselectivities. Only in the case of a sterically hindered *ortho*-toluoyl residue (**2e**) a lower yield of 32% was observed. Acylation with acetic anhydride, pivaloyl and cyclohexanoyl chloride led to the formation of the desired products **2b**, **2a** and **2n** in a 51–69% yield. Reactions with other aliphatic acid chlorides, such as ethanoyl or *n*-propanoyl chloride, afforded the oxyenamides **2c–d** in significantly lower yields of 19–20%. In order to extend the scope of available 2-oxyenamides, we explored the synthesis of derivatives bearing other residues on the amine or oxygen functionality. At first, the incorporation of an electron-withdrawing sulfonyl group was studied. To our delight treatment of aminoaldehyde **3a** with arene sulfonyl chlorides under otherwise identical conditions directly afforded the enolsulfonates **8a–c** in 49–61% yield. Also in these cases, exclusive formation of the *Z*-isomer was observed.

Next, we prepared the phthalimide-derived aminoacetaldehyde dimethyl acetal **9** in 76% from phthalic anhydride and aminoacetaldehyde dimethyl acetal (Scheme 7). Subsequent hydrolysis of **9** with aqueous HCl led to the formation of the phthalimide-derived aminoacetaldehyde **10** in 99% yield. Treatment of **10** with benzoyl chloride, pivaloyl chloride or acetic



Scheme 7. Synthesis of 2-oxyenimides **10a–c**. [a] The reaction was carried out with Ac₂O (1.3 equiv), NEt₃ (1.7 equiv) and DMAP (0.2 equiv).


anhydride afforded the desired 2-oxyenimides **11a–c** in 49–88% yield. Longer reaction times and 1.5–2.0 equivalents of the acylating agent were necessary to ensure complete conversion of the aldehyde **10**. Surprisingly, these transformations afforded a mixture of the two stereoisomers (*E*-**11** and *Z*-**11**). Whereas, acylation with acetic anhydride furnished a 1:1 mixture of the *E*- and the *Z*-isomer of oxyenimide **11a**, a preferential formation

of the *E*-isomers was observed for the pivaloyl- and benzoyl derivatives **11b** and **11c**.


Since oxenimides of type **11** lack a free N–H, one could envision a crucial role of intramolecular hydrogen bonding in the observed stereoselective outcome of the reaction or an additional stabilization of the *Z*-oxenamide products. To further evaluate the role of intermolecular H-bonding, we synthesized the *N*-methylated oxenamide **12**. At first, Bz-protected aminoacetaldehyde dimethyl acetal **5a** was treated with MeI and NaH to afford the *N*-methyl derivative **13** in 98% yield. Hydrolysis of **13** with using our general procedure afforded the corresponding aldehyde (not shown), which proved to be very unstable. Therefore, the crude aldehyde was subjected directly to the acylation with acetic anhydride, furnishing the desired *N*-methylated oxenamide **12** in 31% yield over two steps (Scheme 8). Interestingly a stereoselective formation of the *Z*-isomer (**Z**-**12**) was observed in this case.

Overall, the observed results for the parent oxenamides (**1**/**2**), the oxenimides of type **11** and the *N*-methylated oxenamide **12** provide preliminary evidence, that the N–H group and also intramolecular hydrogen bonding might play key roles in the stereochemical outcome of the reaction. We initially assumed, that stabilization via intramolecular hydrogen bonding leads to a preferred formation of the (*Z*)-enolate (**14**) in equilibrium, resulting in the observed stereoselective generation of the (*Z*)-oxenamides (Scheme 9).

To get a better understanding of the observed diastereoselectivity and to gain further insights into the nature of the oxenamides, we performed a computational analysis for selected structures at the DLPNO-CCSD(T)/Extrapolate(3/4,def2)/SMD(CH₂Cl₂)/M06-2X–D3/6-311 + G(d,p)/SMD(CH₂Cl₂). In this analysis, we focused on the different stabilities of the intermediate oxenamide anions **14** and the final acetylated oxenamides for selected *N*-protected systems. Our calculations indicate very high endergonicities for the initial deprotonations of the parent oxenamide by NEt₃ leading to separated ions, which is most likely caused by the unfavorable charge separation. It can be expected that ion pairs substantially reduce this energy difference, but we did not attempt to determine accurate reaction energies for this step because of the high flexibility of all cation-anion combinations. Instead, we



Scheme 8. Synthesis of the *N*-methylated 2-oxenamide **12**.



Scheme 9. Preliminary mechanistic proposal.

concentrate on the relative Gibbs free energies ($\Delta\Delta G = \Delta G_Z - \Delta G_E$) for representative examples of the anionic intermediates **14** and the final products. Those results are summarized in Table 2 and selected structures are depicted in Figure 3 (see the Supporting Information for more structures).

For the secondary amides **2d,q** and **14a,b** our calculations indicate a strong thermodynamic preference for the *Z*-configured structures. This finding is in good qualitative agreement with the experimental formation of almost exclusively *Z*-configured products. When the N–H group is replaced by N–Me groups (**2r**, **12** and **14c,d**), the energy differences are getting substantially smaller and the additional steric interaction between the methyl and acetyl groups results in a destabilization of the *Z*-configured isomers.

Our DFT calculations further indicate that the π -systems within most acetylated oxenamides are coplanar or slightly distorted due to steric interactions in the *Z*-form. In contrast, many anionic oxenamides feature a perpendicular orientation

Table 2. Relative Gibbs Free Energies $\Delta\Delta G$ (in kJ mol^{-1}) for oxenamide anions and acetylated oxenamides.^[a]

Entry	Structure	$\Delta\Delta G$
1		–21
2		–8
3		–13
4		–11
5		–8
6		–2
7		–6
8		+7
9		+5
10		+2

[a] DLPNO-CCSD(T)/Extrapolate(3/4,def2)/SMD(CH₂Cl₂)/M06-2X–D3/6-311 + G(d,p)/SMD(CH₂Cl₂).




Figure 3. Calculated structures for selected oxenamide anions **14** and their acetylated analogues **2** and **12**.

of the π -systems of the amide and enolate substructures (e.g., **E-14b** in Figure 3). Almost all *E*-configured oxenamide anions as well as *Z*-configured tertiary oxenamides **Z-14c,d** prefer this orientation, while the secondary *Z*-oxenamides **Z-14a,b** feature coplanar structures.

For the experimentally studied anionic systems **14a** and **2d**, the intramolecular N–H...O hydrogen bond contributes 7.5 and 5 kJ mol⁻¹ in the *Z*-isomers according to our NBO analysis,^[15] while no hydrogen bond could be detected in the acetylated species **2d** and **2q**. Thus, the oxenamide anions **14** are at least partially stabilized through this intramolecular hydrogen bond.

Conclusion

In summary, we have developed an improved 2nd generation route for the synthesis of 2-oxenamides. Aminoacetaldehyde dimethyl acetal, a readily available bulk, is used as common building block. Various acylated and sulfonylated oxenamides can be accessed in three steps in a highly modular fashion. The desired products are formed in good yields and the process is amendable to a gram-scale synthesis of oxenamides. All oxenamide products containing a free N–H functionality are formed exclusively as (*Z*)-isomer. In case of *N*-methylated or phthaloyl-based derivatives lacking an N–H-bond, a mixture of the *E*- and *Z*-isomer is obtained. For oxenamides containing a secondary amide, DFT calculations show strong thermodynamic preference for the *Z*-configured product and even more pronounced preference for the intermediate *Z*-enolate. Calculated energy differences for compounds lacking a free N–H functionality are much smaller. Calculations also indicate a

partial stabilization of the *Z*-configured enolates through intramolecular hydrogen bonding. Results from the DFT calculations are in good agreement with our experimental findings.^[16]

Experimental Section

For general experimental conditions, detailed experimental procedures, analytical data, and ¹H, ¹³C and ¹⁹F NMR spectra, as well as computational details see the Supporting Information. The following procedure serves as a representative example.

General procedure (Synthesis of (*Z*)-oxenamides **1/2**)

To a stirred solution of Et₃N (1.7 equiv) and the corresponding acyl chloride (1.3 equiv) in CH₂Cl₂ (2 mL/mmol) was added dropwise a solution of the aldehyde **3** (1.0 equiv) in CH₂Cl₂ (2 mL/mmol) over 5 min. The reaction mixture was stirred for 1 h at room temperature. After TLC analysis showed complete consumption of the aldehyde, saturated NaHCO₃ solution was added (20 mL). The organic layers were separated and the aqueous phase was extracted with CH₂Cl₂ (2 × 30 mL). The combined organic layers were dried over Na₂SO₄, filtered and the solvents were evaporated under reduced pressure. Purification by flash chromatography afforded the desired (*Z*)-oxenamide **1/2** as analytically pure product. All oxenamides of type **1/2** tend to decompose upon contact to any type of acid. Therefore, column chromatography was performed with 0.2 vol% NEt₃ as additive. CDCl₃ for NMR spectroscopy was passed through short plug of basic alumina before use.

Acknowledgements

Financial support by the DFG (MA 6093/10-1 to G.M.; BR 5154/4-1 to M.B.) and the research unit NanoKat at the TU Kaiserslautern is gratefully acknowledged. We thank the Regional Computing Center of the University of Cologne for providing computing time of the DFG-funded (Funding number: INST 216/512/1FUGG) High Performance Computing (HPC) System CHEOPS as well as for their support. Open Access funding enabled and organized by Projekt DEAL.

Conflict of Interest

The authors declare no conflict of interest.

Data Availability Statement

The data that support the findings of this study are available in the supplementary material of this article.

Keywords: Enamides · DFT calculations · Synthetic methods · Enolate · Z-selective

- [1] a) K. Gopalaiah, H. B. Kagan, *Chem. Rev.* **2011**, *111*, 4599–4657; b) T. Courant, G. Dagoussset, G. Masson, *Synthesis* **2015**, *47*, 1799–1826; c) R. Matsubara, S. Kobayashi, *Acc. Chem. Res.* **2008**, *41*, 292–301; d) D. R. Carbery, *Org. Biomol. Chem.* **2008**, *6*, 3455–3460; e) G. Bernadat, G. Masson, *Synlett* **2014**, *25*, 2842–2867; f) P. Kramer, G. Manolikakes, *Synlett* **2020**, *31*, 1027–1032; g) T. Varlet, G. Masson, *Chem. Commun.* **2021**, *57*, 4089–4105.
- [2] For some selected recent examples see: a) J. Halli, M. Bolte, J. Bats, G. Manolikakes, *Org. Lett.* **2017**, *19*, 674–677; b) J. Halli, P. Kramer, J. Grimmer, M. Bolte, G. Manolikakes, *J. Org. Chem.* **2018**, *83*, 12007–12022; c) P. Kramer, J. Grimmer, M. Bolte, G. Manolikakes, *Angew. Chem. Int. Ed.* **2019**, *58*, 13056–13059; *Angew. Chem.* **2019**, *131*, 13190–13193; d) A. Dumoulin, G. Bernadat, G. Masson, *J. Org. Chem.* **2017**, *82*, 775–1789; e) J. Lyu, A. Claraz, M. R. Vitale, C. Allain, G. Masson, *J. Org. Chem.* **2020**, *85*, 12843–12855; f) M. Kretzschmar, T. Hodik, C. Schneider, *Angew. Chem. Int. Ed.* **2016**, *55*, 9788–9792; *Angew. Chem.* **2016**, *128*, 9941–9946; g) G. Levitre, C. Audubert, A. Dumoulin, N. Goual, P. Retailleau, X. Moreau, G. Masson, *ChemCatChem* **2019**, *11*, 5723–5727; h) R. J. Phipps, K. Hiramatsu, F. D. Toste, *J. Am. Chem. Soc.* **2012**, *134*, 8376–8379; i) W.-Y. Ma, C. Gelis, D. Bouchet, P. Retailleau, X. Moreau, L. Neuville, G. Masson, *Org. Lett.* **2021**, *23*, 442–448; j) F. de Nanteuil, J. Waser, *Angew. Chem. Int. Ed.* **2013**, *52*, 9009–9013; *Angew. Chem.* **2013**, *125*, 9179–9183; k) E. Richmond, I. U. Khan, J. Moran, *Chem. Eur. J.* **2016**, *22*, 12274–12277; l) M. Terada, K. Sorimachi, *J. Am. Chem. Soc.* **2007**, *129*, 292–293; m) Y. Shen, M.-L. Shen, P.-S. Wang, *ACS Catal.* **2020**, *10*, 8247–8253; n) X.-Y. Bai, W.-W. Zhang, Q. Li, B.-J. Li, *J. Am. Chem. Soc.* **2018**, *140*, 506–514; o) J. Kikuchi, N. Momiyama, M. Terada, *Org. Lett.* **2016**, *18*, 2521–2523.
- [3] a) D. Siodlak, *Amino Acids* **2015**, *47*, 1–17; b) T. Kuranaga, Y. Sesoko, M. Inoue, *Nat. Prod. Rep.* **2014**, *31*, 514–532; c) B. B. Snider, F. Song, *Chem. Rev.* **2003**, *103*, 4283–4306.
- [4] For some isolated examples, see: application: a) T. Hashimoto, H. Nakatsu, Y. Takigushi, K. Maruoka, *J. Am. Chem. Soc.* **2013**, *135*, 16010–16013 (only one example with an oxenamide); b) P. D. Howes, P. W. Smith, *Tetrahedron Lett.* **1996**, *37*, 6595–6598; c) M. C. Cesa, R. A. Dubbert, J. D. Burrington, US Patent US 4929755 A 19900529, **1990**; d) T. Lechel, H.-U. Reissig, *Eur. J. Org. Chem.* **2010**, 2555–2564; e) P. Etayo, J. L. Núñez-Rico, H. Fernández-Pérez, A. Vidal-Ferran, *Chem. Eur. J.* **2011**, *17*, 13978–13982; f) Y.-Q. Guan, M. Gao, X. Deng, H. Lv, X. Zhang, *Chem. Commun.* **2017**, *53*, 8136–8139; synthesis: g) G. K. Min, D. Hernandez, A. T. Lindhart, T. Skrydstrup, *Org. Lett.* **2010**, *12*, 4716–4719; h) P. García-Reynaga, A. K. Carrillo, M. S. VanNieuwenhze, *Org. Lett.* **2012**, *14*, 1030–1033; i) R. Mazurkiewicz, A. Pazdzierniak-Holewa, B. Orlinska, S. Stecko, *Tetrahedron Lett.* **2009**, *50*, 4606–4609; j) K. Okamoto, M. Sakagami, F. Feng, H. Togame, H. Takemoto, S. Ichikawa, A. Matsuda, *Org. Lett.* **2011**, *13*, 5240–5243.
- [5] a) J. A. Deyrup, H. L. Gingrich, *Tetrahedron Lett.* **1977**, *18*, 3115–3118; b) K.-H. Scholz, H.-G. Heine, W. Hartmann, *Liebigs Ann. Chem.* **1977**, 2027–2035; c) S. V. D'Andrea, J. P. Freeman, J. Szmuszkovicz, *J. Org. Chem.* **1990**, *55*, 4356–4358; d) H. Matsunaga, K. Kimura, T. Ishizuka, M. Haratake, T. Kunieda, *Tetrahedron Lett.* **1991**, *32*, 7715–7718; e) K. Kimura, K. Murata, K. Otsuka, T. Ishizuka, M. Haratake, T. Kunieda, *Tetrahedron Lett.* **1992**, *33*, 4461–4464; f) N. Hashimoto, T. Ishizuka, T. Kunieda, *Tetrahedron Lett.* **1994**, *35*, 721–724; g) H. Matsunaga, T. Ishizuka, T. Kunieda, *Tetrahedron* **1997**, *53*, 1275–1294; h) K.-H. Scholz, H.-G. Heine, W. Hartmann, *Tetrahedron Lett.* **1978**, 1467–1470; i) S. P. Fearnley, E. Market, *Chem. Commun.* **2002**, 438–439; j) I. Nomura, C. Mukai, *Org. Lett.* **2002**, *4*, 4301–4304.
- [6] a) J. P. Karwowski, M. Jackson, R. J. Theriault, R. H. Chen, G. J. Barlow, M. L. Maus, *J. Antibiot.* **1989**, *42*, 506–511; b) R. H. Chen, A. M. Buko, D. N. Whittern, J. B. McAlpine, *J. Antibiot.* **1989**, *42*, 512–520; c) P. B. Fernandes, R. N. Swanson, D. J. Hardy, C. W. Hanson, L. Coen, R. R. Rasmussen, R. H. Chen, *J. Antibiot.* **1989**, *42*, 521–526; d) R. M. Fronko, J. C. Lee, J. G. Galazzo, S. Chamberland, F. Malouin, M. D. Lee, *J. Antibiot.* **2000**, *53*, 1405–1410; e) K. Okamoto, M. Sakagami, F. Feng, H. Togame, H. Takemoto, S. Ichikawa, A. Matsuda, *J. Org. Chem.* **2012**, *77*, 1367–1377.
- [7] a) Y. Xie, R. Chen, S. Si, C. Sun, H. Xu, *J. Antibiot.* **2007**, *60*, 158–161; b) Y. Xie, H. Xu, S. Si, C. Sun, R. Chen, *J. Antibiot.* **2008**, *61*, 237–240; c) Y. Xie, H. Xu, C. Sun, Y. Yu, R. Chen, *J. Antibiot.* **2010**, *63*, 143–146.
- [8] a) T. Iizuka, R. Fudou, Y. Jojima, S. Ogawa, S. Yamanaka, Y. Inukai, M. Ojika, *J. Antibiot.* **2006**, *59*, 385–391; b) M. Ojika, Y. Inukai, Y. Kito, M. Hirata, T. Iizuka, R. Fudou, *Chem. Asian J.* **2008**, *3*, 126–133; c) L. Karmann, K. Schultz, J. Herrmann, R. Müller, U. Kazmaier, *Angew. Chem. Int. Ed.* **2015**, *54*, 4502–4507; *Angew. Chem.* **2015**, *127*, 4585–4590.
- [9] S.-C. Krieg, J. Grimmer, P. Kramer, M. Bolte, H. Kelm, G. Manolikakes, *Angew. Chem. Int. Ed.* **2021**, *60*, 23667–23671; *Angew. Chem.* **2021**, *133*, 23859–23864.
- [10] a) For a general overview on the nucleophilicity, see the Mayr database: <https://www.cup.lmu.de/oc/mayr/reaktionsdatenbank/> and T. B. Phan, M. Breugst, H. Mayr, *Angew. Chem. Int. Ed.* **2006**, *45*, 3869–3874; *Angew. Chem.* **2006**, *118*, 3954–3959; b) For the nucleophilicity of enamides, see: B. Maji, S. Lakhdar, H. Mayr, *Chem. Eur. J.* **2012**, *18*, 5732–5740; c) For the nucleophilicity of enol ethers, see: H. Mayr, B. Kempf, A. R. Ofial, *Acc. Chem. Res.* **2003**, *36*, 66–77.
- [11] T. J. Cousineau, S. L. Cook, J. A. Secrist III, *Synth. Commun.* **1979**, *9*, 157–163.
- [12] Configuration of the double bond could be assigned via the 3J coupling constants of the olefinic protons. Assignment using vicinal coupling constants was verified by deposited single crystal X-ray structures. Deposition Numbers 2180323 (1a), 2180324 (E-11 c), 2180325 (Z-11 c) and 2180326 (Z-12) contain the supplementary crystallographic data for this paper. These data are provided free of charge by the joint Cambridge Crystallographic Data Centre and Fachinformationszentrum Karlsruhe Access Structures service www.ccdc.cam.ac.uk/structures. Configurations of all other compounds were assigned by analogy based on ^1H and ^{13}C NMR spectroscopy.
- [13] In Germany, IBX can only be obtained as stabilized mixture containing 39–45 wt% IBX. Throughout this study, pure IBX has to be synthesized according to: M. Frigerio, M. Santagostino, S. Sputore, *J. Org. Chem.* **1999**, *64*, 4537–4538.
- [14] W. J. Greenlee, P. L. Allibone, D. S. Perlow, A. A. Patchett, E. H. Ulm, T. C. Vassil, *J. Med. Chem.* **1985**, *28*, 434–442.
- [15] E. D. Glendening, J. K. Badenhop, A. E. Reed, J. E. Carpenter, J. A. Bohmann, C. M. Morales, C. R. Landis, F. Weinhold, Theoretical Chemistry Institute, University of Wisconsin, Madison, 2013.
- [16] An initial version of this work was deposited in ChemRxiv on Jun 22, 2022: S.-C. Krieg, J. Grimmer, A. M. Pick, H. Kelm, M. Breugst, G. Manolikakes, *Stereoselective Synthesis of 2-Oxyenamides*, *ChemRxiv* **2022**, DOI: 10.26434/chemrxiv-2022-59zww.

Manuscript received: June 28, 2022
Revised manuscript received: July 15, 2022
Accepted manuscript online: July 18, 2022